NCT04806113 (COVIAAD) is a Phase 3 clinical trial of Moderna COVID-19 vaccine in Covid19, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre.

What drugs are being tested in NCT04806113?

Interventions in NCT04806113: Moderna COVID-19 vaccine.

What condition does NCT04806113 study?

NCT04806113 studies Covid19, Rheumatic Diseases, Rheumatoid Arthritis, SLE.

Is NCT04806113 still recruiting?

NCT04806113 is currently completed. Last updated 20 March 2023.

Last reviewed 2023-03-20 · How we verify

NCT04806113: COVIAAD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases

Completed Phase 3 Last updated 20 March 2023

What this trial tests

Phase 3 trial testing Moderna COVID-19 vaccine in Covid19 in 220 participants. Completed in 15 June 2022.

Timeline

11 March 2021

Primary endpoint
13 June 2021

15 June 2022

Quick facts

Lead sponsor	McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	220
Start date	11 March 2021
Primary completion	13 June 2021
Estimated completion	15 June 2022
Sites	1 location across Canada

Drugs / interventions tested

Moderna COVID-19 vaccine — full drug profile →

Conditions studied

Covid19 — all drugs for Covid19 →
Rheumatic Diseases — all drugs for Rheumatic Diseases →
Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →
SLE — all drugs for SLE →

Sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Who can join

18 and older, any sex, with Covid19 or Rheumatic Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the Moderna RNA-based COVID-19 vaccine currently approved by Health Canada in people with rheumatic diseases. This study will help understand what the side effects of the vaccine in these patients are, and what is their capacity to develop antibodies that may confer protection from the COVID-19 disease.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

mRNA vaccines for infectious diseases: principles, delivery and clinical translation.
Chaudhary N, Weissman D, Whitehead KA. · · 2021 · cited 1014× · PMID 34433919 · DOI 10.1038/s41573-021-00283-5
Advances in COVID-19 mRNA vaccine development.
Fang E, Liu X, Li M, Zhang Z, et al · · 2022 · cited 368× · PMID 35322018 · DOI 10.1038/s41392-022-00950-y
COVID-19 mRNA vaccines: Platforms and current developments.
Szabó GT, Mahiny AJ, Vlatkovic I. · · 2022 · cited 198× · PMID 35189345 · DOI 10.1016/j.ymthe.2022.02.016
COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety.
Luxi N, Giovanazzi A, Capuano A, Crisafulli S, et al · · 2021 · cited 98× · PMID 34739716 · DOI 10.1007/s40264-021-01131-6
COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials.
Yan ZP, Yang M, Lai CL. · · 2021 · cited 89× · PMID 33923054 · DOI 10.3390/ph14050406
mRNA vaccines: the most recent clinical applications of synthetic mRNA.
Kwon S, Kwon M, Im S, Lee K, et al · · 2022 · cited 50× · PMID 35426547 · DOI 10.1007/s12272-022-01381-7
Delivery Routes for COVID-19 Vaccines.
Park JH, Lee HK. · · 2021 · cited 48× · PMID 34069359 · DOI 10.3390/vaccines9050524
Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects.
Zhang Z, Shen Q, Chang H. · · 2022 · cited 44× · PMID 35572592 · DOI 10.3389/fimmu.2022.843928

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other McGill University Health Centre/Research Institute of the McGill University Health Centre trials

Trials by the same sponsor.

NCT07439406 — Comparing Standard and Autoclaved Peanut Oral Immunotherapy in People With Peanut Allergy · Phase 2 · not yet recruiting
NCT07328971 — Vancomycin Taper to Prevent Recurrent Clostridioides Difficile · Phase 3 · not yet recruiting
NCT07556952 — Dex & Mastectomy Pain · Phase 4 · recruiting
NCT07069582 — Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women · Phase 1 · not yet recruiting
NCT07386171 — Micro-Ultrasound for Detecting Clinically Significant Prostate Cancer in Active Surveillance · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04806113 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by McGill University Health Centre/Research Institute of the McGill University Health Centre
Last refreshed: 20 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04806113.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing